Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

18. November 2019 02:00 ET | Quelle: Arvelle Therapeutics

Risultati di uno studio randomizzato che valuta la sicurezza e l'efficacia del cenobamate nei pazienti con epilessia focale non controllata pubblicato su The Lancet Neurology

ZUG, Svizzera, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Arvelle Therapeutics GmbH, una società biofarmaceutica emergente focalizzata su trattamenti innovativi per pazienti con disturbi del sistema nervoso...
15. November 2019 02:00 ET | Quelle: Arvelle Therapeutics

Arvelle to Present at Jefferies 2019 London Healthcare Conference

Arvelle to Present at Jefferies 2019 London Healthcare Conference Zug, Switzerland, November 15, 2019 - Arvelle Therapeutics GmbH (“Arvelle”), an emerging biopharmaceutical company focused on...
14. November 2019 02:00 ET | Quelle: Arvelle Therapeutics

Results of Randomized Study Evaluating the Safety and Efficacy of Cenobamate in Patients with Uncontrolled Focal-Onset Epilepsy Published in The Lancet Neurology

ZUG, Switzerland, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Arvelle Therapeutics GmbH, an emerging biopharmaceutical company focused on bringing innovative treatments to patients with CNS disorders, today...
31. Oktober 2019 02:00 ET | Quelle: Arvelle Therapeutics

Arvelle Therapeutics Strengthens Management Team with Key New Hires

Arvelle Therapeutics Strengthens Management Team with Key New Hires Appoints Petra Molan as Senior Vice President Commercial and Enrico Dolfini as...

Vorherige Seite